Dynamic vaccine blocks relapse to compulsive intake of heroin

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 22, 2013, Pages 9036-9041

  Schlosburg, Joel E ^a   Vendruscolo, Leandro F ^a   Bremer, Paul T ^a   Lockner, Jonathan W ^a   Wade, Carrie L ^a   Nunes, Ashlee A K ^a   Stowe, G Neil ^a   Edwards, Scott ^a   Janda, Kim D ^a   Koob, George F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antinociception; Immunotherapy; Progressive ratio

Indexed keywords

DIAMORPHINE; DRUG METABOLITE; HEROIN VACCINE; MORPHINE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ARTICLE; COMPULSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABUSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SEEKING BEHAVIOR; DRUG SELECTIVITY; HEROIN DEPENDENCE; IMMUNE SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; VACCINATION;

ANTINOCICEPTION; IMMUNOTHERAPY; PROGRESSIVE RATIO;

ANIMALS; ANTIBODIES; CHROMATOGRAPHY, LIQUID; HEROIN; HEROIN DEPENDENCE; MALE; MORPHINE; MORPHINE DERIVATIVES; MOTIVATION; RATS; RATS, WISTAR; RECURRENCE; SELF ADMINISTRATION; TANDEM MASS SPECTROMETRY; VACCINES;

RATTUS;

EID: 84878467308     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1219159110     Document Type: Article

References (45)

1. Degenhardt L, Hall W (2012) Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 379(9810):55-70.
2. United Nations Office for Drug Control and Crime Prevention (2012) World Drug Report 2012 (United Nations, Vienna, Austria), p 112.
3. Nutt DJ, King LA, Phillips LD; Independent Scientific Committee on Drugs (2010) Drug harms in the UK: A multicriteria decision analysis. Lancet 376(9752):1558-1565.
4. Mayet S, Farrell M, Ferri M, Amato L, Davoli M (2005) Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst Rev (1):CD004330.
5. Farrell M, et al. (1994) Methadone maintenance treatment in opiate dependence: A review. BMJ 309(6960):997-1001.
6. Kakko J, Svanborg KD, Kreek MJ, Heilig M (2003) 1-year retention and social function after buprenorphine-Assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet 361(9358):662-668.
7. Blanken P, Hendriks VM, van Ree JM, van den Brink W (2010) Outcome of long-term heroin-Assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction 105(2):300-308.
8. Miller NS, Gold MS (2007) Opiate prescription medication dependence and pain perceptions. J Addict Dis 26(Suppl 1):65-71.
9. Centers for Disease Control and Prevention (CDC) (2012) Vital signs: Risk for overdose from methadone used for pain relief -United States, 1999-2010. MMWR Morb Mortal Wkly Rep 61(26):493-497.
10. Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P (2009) Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 104(1-2):73-77.
11. Mégarbane B, et al. (2010) Prospective comparative assessment of buprenorphine overdose with heroin and methadone: Clinical characteristics and response to antidotal treatment. J Subst Abuse Treat 38(4):403-407.
12. Malcolm R, O'Neil PM, Von JM, Dickerson PC (1987) Naltrexone and dysphoria: A double-blind placebo controlled trial. Biol Psychiatry 22(6):710-716.
13. Crowley TJ, Wagner JE, Zerbe G, Macdonald M (1985) Naltrexone-induced dysphoria in former opioid addicts. Am J Psychiatry 142(9):1081-1084.
14. Bronstein DM, Day NC, Gutstein HB, Trujillo KA, Akil H (1993) Pre-And posttranslational regulation of beta-endorphin biosynthesis in the CNS: Effects of chronic naltrexone treatment. J Neurochem 60(1):40-49.
15. Kosten TR, Kreek MJ, Ragunath J, Kleber HD (1986) A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. Life Sci 39(1):55-59.
16. Ritter AJ (2002) Naltrexone in the treatment of heroin dependence: Relationship with depression and risk of overdose. Aust N Z J Psychiatry 36(2):224-228.
17. Hatsukami DK, et al. (2005) Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 78(5):456-467.
18. Kosten TR, et al. (2002) Human therapeutic cocaine vaccine: Safety and immunogenicity. Vaccine 20(7-8):1196-1204.
19. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR (2005) Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 58(2):158-164.
20. Selley DE, et al. (2001) mu Opioid receptor-mediated G-protein activation by heroin metabolites: Evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. Biochem Pharmacol 62(4):447-455.
21. Stowe GN, et al. (2011) Developing a vaccine against multiple psychoactive targets: A case study of heroin. CNS Neurol Disord Drug Targets 10(8):865-875.
22. Anton B, Leff P (2006) A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 24(16):3232-3240.
23. Li QQ, et al. (2011) A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats. J Neurochem 119(6):1271-1281.
24. Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR (1974) Changes in heroin self-Administration by a rhesus monkey after morphine immunisation. Nature 252(5485):708-710.
25. Stowe GN, et al. (2011) A vaccine strategy that induces protective immunity against heroin. J Med Chem 54(14):5195-5204.
26. Raleigh MD, Pravetoni M, Harris AC, Birnbaum AK, Pentel PR (2013) Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroininduced behaviors in rats. J Pharmacol Exp Ther 344(2):397-406.
27. Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH (2006) Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: Review of the literature. Curr Clin Pharmacol 1(1):109-118.
28. Rook EJ, et al. (2006) Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioiddependent patients. Basic Clin Pharmacol Toxicol 98(1):86-96.
29. Oguri K, Hanioka N, Yoshimura H (1990) Species differences in metabolism of codeine: Urinary excretion of codeine glucuronide, morphine-3-glucuronide and morphine-6-glucuronide in mice, rats, guinea pigs and rabbits. Xenobiotica 20(7): 683-688.
30. Banna KM, Back SE, Do P, See RE (2010) Yohimbine stress potentiates conditioned cue-induced reinstatement of heroin-seeking in rats. Behav Brain Res 208(1):144-148.
31. Bossert JM, Poles GC, Wihbey KA, Koya E, Shaham Y (2007) Differential effects of blockade of dopamine D1-family receptors in nucleus accumbens core or shell on reinstatement of heroin seeking induced by contextual and discrete cues. J Neurosci 27(46):12655-12663.
32. Lenoir M, Ahmed SH (2007) Heroin-induced reinstatement is specific to compulsive heroin use and dissociable from heroin reward and sensitization. Neuropsychopharmacology 32(3):616-624.
33. Chen SA, et al. (2006) Unlimited access to heroin self-Administration: Independent motivational markers of opiate dependence. Neuropsychopharmacology 31(12): 2692-2707.
34. Vendruscolo LF, et al. (2011) Escalation patterns of varying periods of heroin access. Pharmacol Biochem Behav 98(4):570-574.
35. Koob GF, Pettit HO, Ettenberg A, Bloom FE (1984) Effects of opiate antagonists and their quaternary derivatives on heroin self-Administration in the rat. J Pharmacol Exp Ther 229(2):481-486.
36. Li Q, et al. (2012) Craving correlates with mesolimbic responses to heroin-related cues in short-term abstinence from heroin: An event-related fMRI study. Brain Res 1469: 63-72.
37. Zijlstra F, Booij J, van den Brink W, Franken IH (2008) Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males. Eur Neuropsychopharmacol 18(4):262-270.
38. Franken IH, Hendriks VM, Stam CJ, Van den BrinkW(2004) A role for dopamine in the processing of drug cues in heroin dependent patients. Eur Neuropsychopharmacol 14(6):503-508.
39. Pravetoni M, et al. (2012) An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. J Pharmacol Exp Ther 341(1):225-232.
40. Pravetoni M, et al. (2013) Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. J Med Chem 56(3):915-923.
41. Pravetoni M, et al. (2012) Co-Administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine 30(31):4617-4624.
42. Dixon WJ (1980) Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20:441-462.
43. Karinen R, et al. (2009) Determination of heroin and its main metabolites in small sample volumes of whole blood and brain tissue by reversed-phase liquid chromatography-tandem mass spectrometry. J Anal Toxicol 33(7):345-350.
44. Stinus L, Cador M, Zorrilla EP, Koob GF (2005) Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology 30(1):90-98.
45. Caine SB, Koob GF (1993) Modulation of cocaine self-Administration in the rat through D-3 dopamine receptors. Science 260(5115):1814-1816.